High‐dose daunorubicin therapy for acute nonlymphocytic leukemia: Correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity

Daunorubicin, administered in large doses intermittently to 23 patients with acute nonlymphocytic leukemia (ANLL), produced a complete hematologic remission rate of 33%. Five of 16 (31%) previously untreated patients achieved complete hematologic remission. Clinical response was closely correlated with in vitro determinations of peripheral leukemic myeloblast daunorubicin reductase activity. The measurement of the activity of daunorubicin reductase in peripheral myeloblasts from patients with ANLL prior to therapy may serve to identify those patients least likely to respond favorably to daunorubicin therapy in the dose and schedule used in this study.

[1]  P. Wiernik,et al.  A randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia. , 1972, Cancer research.

[2]  N. Bachur,et al.  Daunorubicin metabolism in acute myelocytic leukemia. , 1972, Blood.

[3]  D. Huffman,et al.  Daunorubicin metabolism: estimation of daunorubicin reductase , 1971, British Journal of Pharmacology.

[4]  J. Bertino,et al.  L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. , 1971, Annals of internal medicine.

[5]  G. Fairley.  THE TREATMENT OF ACUTE MYELOBLASTIC LEUKAEMIA , 1971, British journal of haematology.

[6]  W Satterlee,et al.  Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. , 1971, The New England journal of medicine.

[7]  D. Alberts,et al.  The pharmacokinetics of daunomycin in man , 1971, Clinical pharmacology and therapeutics.

[8]  N. Bachur,et al.  Daunomycin metabolism in rat tissue slices. , 1970, The Journal of pharmacology and experimental therapeutics.

[9]  P. Wiernik,et al.  FACTORS EFFECTING REMISSION AND SURVIVAL IN ADULT ACUTE NONLYMPHOCYTIC LEUKEMIA (ANLL) , 1970, Medicine.

[10]  M. Boiron,et al.  Current status: treatment of acute leukemia. , 1970, Seminars in hematology (Print).

[11]  S. Perry.  Reduction of toxicity in cancer chemotherapy. , 1969, Cancer research.

[12]  B. Clarkson,et al.  Treatment of adult acute leukemia with arabinosylcytosine and thioguanine , 1969, Cancer.

[13]  F. Bauters,et al.  [Treatment of acute myeloblastic leukemia by rubidomycin. Statistics on 35 cases]. , 1969, Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille.

[14]  R. Bornstein,et al.  Daunorubicine in acute myelogenous leukemia in adults. , 1969, JAMA.

[15]  M. Boiron,et al.  Daunorubicin in the treatment of acute myelocytic leukaemia. , 1969, Lancet.

[16]  E. Henderson.  Treatment of acute leukemia. , 1969, Seminars in hematology.

[17]  C. Spurr,et al.  Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. , 1968, Blood.

[18]  D. Karnofsky,et al.  Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia , 1967, Cancer.

[19]  T. Han,et al.  Effect of platelet transfusion on hemorrhage in patients with acute leukemia: An autopsy study , 1966, Cancer.

[20]  D. Burk,et al.  Leukocyte preparations from human blood: evaluation of their morphologic and metabolic state. , 1962, The Journal of laboratory and clinical medicine.